Although the number of patients was small, this study is important because we tested and confirmed the efficacy of the anti-CD38 monoclonal antibody daratumumab in AL Amyloidosis without significant toxicity related to the drug in a real-life population. Here, CD38 is linked to AL amyloidosis.